Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Escalation Study of INCB050465 in Pemphigus Vulgaris
2018-002146-37Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of parsaclisib in pemphigus vulgaris (PV) (3 cohorts), sponsored by Incyte. Primary endpoint: Safety and tolerability of INCB050465. Started Oct 2018; status: completed.
02
Drugs
parsaclisib
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on 2018-002146-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002146-37.